

31 October 2025

Dear Shareholders

GENERAL MEETING

Kuniko Limited (ASX:KNI) (the **Company**) is convening a General Meeting of shareholders to be held on 3 December 2025 at 2:30pm (WST) at Level 1, 1 Alvan Street, Subiaco WA 6008 (**Meeting**).

The Company will not be sending hard copies of the Notice of Meeting to shareholders unless a shareholder has requested a hard copy. The Notice of Meeting and Explanatory Memorandum can be viewed and downloaded from the link set out below.

<https://kuniko.eu/investment-centre/>

Alternatively, a complete copy of the Notice of Meeting and Explanatory Statement has been posted on the Company's ASX market announcements page.

The Company **strongly encourages Shareholders to lodge a directed proxy form prior to the meeting and register their attendance prior to the Meeting if they intend to attend.** Questions should also be submitted in advance of the Meeting as this will provide management with the best opportunity to prepare for the meeting, for example by preparing answers in advance to Shareholders questions. However, votes and questions may also be submitted during the Meeting.

If you have nominated an email address and have elected to receive electronic communications from the Company, you will also receive an email to your nominated email address with a link to an electronic copy of the Notice of Meeting and Explanatory Statement.

In order to receive electronic communications from the Company in the future, please update your Shareholder details online at <https://investor.automic.com.au/#/home> and log in with your unique shareholder identification number and postcode (or country for overseas residents), where you can find on your enclosed personalised proxy form. Once logged in you can also lodge your proxy vote online by clicking on the "Vote" tab.

If you are unable to access the Notice of Meeting and Explanatory Memorandum online please contact the Company Secretary, Joel Ives, on +61 8 6364 5095 or via email at info@kuniko.eu.

The Notice of Meeting and Explanatory Memorandum are important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser, lawyer, accountant or other professional adviser.

This announcement is authorised for market release by the Company Secretary of Kuniko Limited.

Sincerely,

Joel Ives

Joint Company Secretary

KUNIKO LIMITED
ACN 619 314 055
NOTICE OF GENERAL MEETING

Notice is given that the Meeting will be held at:

TIME: 2:30pm (WST)
DATE: 3 December 2025
PLACE: Level 1
1 Alvan Street
SUBIACO WA 6008

The business of the Meeting affects your shareholding and your vote is important.

This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 4:00pm (WST) on 1 December 2025.

BUSINESS OF THE MEETING

AGENDA

1. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF FEE SHARES TO IMPACT MINERALS LIMITED

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 250,000 Shares to Impact Minerals Limited on the terms and conditions set out in the Explanatory Statement."

2. RESOLUTION 2 – RATIFICATION OF PRIOR ISSUE OF COMPLETION SHARES TO IMPACT MINERALS LIMITED

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 2,875,000 Shares to Impact Minerals Limited on the terms and conditions set out in the Explanatory Statement."

3. RESOLUTION 3 – APPROVAL TO ISSUE UNDERWRITING FEE OPTIONS TO GBA CAPITAL

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue 5,808,285 Underwriting Fee Options to GBA Capital Pty Ltd (or its nominee(s)) on the terms and conditions set out in the Explanatory Statement."

4. RESOLUTION 4 – APPROVAL TO ISSUE SHORTFALL SECURITIES TO RELATED PARTY – MAJA MCGUIRE

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 244,420 Shares and 81,474 Attaching Options to Maja McGuire (or her nominee(s)) on the terms and conditions set out in the Explanatory Statement."

5. RESOLUTION 5 – RATIFICATION OF PRIOR ISSUE OF SHARES UNDER TOP-UP PLACEMENT

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 9,796,755 Shares to the Top-up Placement Participants on the terms and conditions set out in the Explanatory Statement."

6. RESOLUTION 6 – APPROVAL TO ISSUE ATTACHING OPTIONS UNDER TOP-UP PLACEMENT

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue 3,265,585 Attaching Options to the Top-up Placement Participants on the terms and conditions set out in the Explanatory Statement."

7. RESOLUTION 7 – APPROVAL TO ISSUE TOP-UP FEE OPTIONS TO GBA CAPITAL

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue 1,959,351 Top-up Fee Options to GBA Capital Pty Ltd (or its nominee(s)) on the terms and conditions set out in the Explanatory Statement."

8. RESOLUTION 8 – APPROVAL TO ISSUE ADVISOR OPTIONS TO AT CAPITAL EQUITY PTY LTD

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to 1,250,000 Advisor Options to AT Capital Equity Pty Ltd (or its nominee(s)) on the terms and conditions set out in the Explanatory Statement."

9. RESOLUTION 9 – APPROVAL TO ISSUE PERFORMANCE RIGHTS TO GAVIN REZOS

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

"That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 6,000,000 Performance Rights to Gavin Rezos (or his nominee(s)) on the terms and conditions set out in the Explanatory Statement."

10. RESOLUTION 10 – APPROVAL TO ISSUE PERFORMANCE RIGHTS TO BRENDAN BORG

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

"That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 4,500,000 Performance Rights to Brendan Borg (or his nominee(s)) on the terms and conditions set out in the Explanatory Statement."

11. RESOLUTION 11 – APPROVAL TO ISSUE PERFORMANCE RIGHTS TO MAJA MCGUIRE

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

"That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 4,500,000 Performance Rights to Maja McGuire (or her nominee(s)) on the terms and conditions set out in the Explanatory Statement."

Dated: 28 October 2025

Voting Prohibition Statements

Resolution 9 – Approval to Issue Performance Rights to Gavin Rezos	In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (Resolution 9 Excluded Party). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolution 9 Excluded Party. In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. Provided the Chair is not a Resolution 9 Excluded Party, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.
Resolution 10 – Approval to Issue Performance Rights to Brendan Borg	In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (Resolution 10 Excluded Party). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolution 10 Excluded Party. In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. Provided the Chair is not a Resolution 10 Excluded Party, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.
Resolution 11 – Approval to Issue Performance Rights to Maja McGuire	In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (Resolution 11 Excluded Party). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolution 11 Excluded Party. In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. Provided the Chair is not a Resolution 11 Excluded Party, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.

Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons:

Resolution 1 – Ratification of Prior Issue of Tranche 1 Consideration Shares to Impact Minerals Limited	Impact Minerals Limited or any other person who participated in the issue of the Consideration Shares or an associate of that person or those persons.
Resolution 2 – Ratification of Prior Issue of Tranche 2 Consideration Shares to Impact Minerals Limited	Impact Minerals Limited or any other person who participated in the issue of the Consideration Shares or an associate of that person or those persons.
Resolution 3 – Approval to Issue Underwriting Fee Options to GBA Capital	GBA Capital Pty Ltd (or its nominee(s)) or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue of Underwriting Fee Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
Resolution 4 – Approval to Issue Shortfall Securities to Related Party – Maja McGuire	Ms Maja McGuire (or her nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of Shortfall Securities to Maja McGuire pursuant to the Director Participation in the Shortfall Offer (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
Resolution 5 – Ratification of Prior Issue of Shares Under Top-Up Placement	The Top-up Placement Participants or any other person who participated in the issue of Shares under the Top-up Placement or an associate of that person or those persons.
Resolution 6 – Approval to Issue Attaching Options Under Top-Up Placement	The Top-up Placement Participants or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue of Attaching Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
Resolution 7 – Approval to Issue Top-Up Fee Options to GBA Capital	GBA Capital Pty Ltd (or its nominee(s)) or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue of Top-up Fee Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
Resolution 8 – Approval to Issue Advisor Options to AT Capital Equity Pty Ltd	AT Capital Equity Pty Ltd (or its nominee(s)) or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue of Advisor Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
Resolution 9 – Approval to Issue Performance Rights to Gavin Rezos	Mr Gavin Rezos (or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of Performance Rights (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.
Resolution 10 – Approval to Issue Performance Rights to Brendan Borg	Mr Brendan Borg (or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of Performance Rights (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.
Resolution 11 – Approval to Issue Performance Rights to Maja McGuire	Ms Maja McGuire (or her nominee(s)) and any other person who will obtain a material benefit as a result of the issue of Performance Rights (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or
- (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting by proxy

To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

Shareholders and their proxies should be aware that:

- if proxy holders vote, they must cast all directed proxies as directed; and
- any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed.

Voting in person

To vote in person, attend the Meeting at the time, date and place set out above.

You may still attend the Meeting and vote in person even if you have appointed a proxy. If you have previously submitted a Proxy Form, your attendance will not revoke your proxy appointment unless you actually vote at the Meeting for which the proxy is proposed to be used, in which case, the proxy's appointment is deemed to be revoked with respect to voting on that Resolution.

Please bring your personalised Proxy Form with you as it will help you to register your attendance at the Meeting. If you do not bring your Proxy Form with you, you can still attend the Meeting but representatives from Automic Registry Services will need to verify your identity. You can register from 2:00pm (WST) on the day of the Meeting.

Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary on +61 8 6364 5095.

EXPLANATORY STATEMENT

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

1. RESOLUTIONS 1 AND 2 – RATIFICATION OF PRIOR ISSUE OF CONSIDERATION SHARES TO IMPACT MINERALS LIMITED

1.1 General

As announced on 4 September 2025, the Company entered into a binding agreement on or about 4 September 2025 (**Impact Agreement**) to earn-in a 70% interest (**Earn-In**) in a joint venture with Impact Minerals Limited (ACN 119 062 261) (ASX:IPT) (**Impact**) and Impact's wholly-owned subsidiary, Endeavour Minerals Pty Ltd (ACN 063 725 708) (**Endeavour**), in respect to the Commonwealth Project located in the Lachlan Fold Belt in New South Wales.

As part consideration for the Earn-In, the Company agreed to issue an aggregate of 3,125,000 Shares to Impact (or its nominee(s)), comprising:

- (a) 250,000 Shares within 5 business days of the execution date of the Impact Agreement (**Fee Shares**), being the subject of Resolution 1; and
- (b) 2,875,000 Shares, subject to, and upon completion occurring under the Impact Agreement (**Completion Shares**), being the subject of Resolution 2,

(together, the **Consideration Shares**).

The Completion Shares will be subject to voluntary escrow, comprising 50% of the Completion Shares for a period of six (6) months from the date of issue and 50% of the Completion Shares for a period of twelve (12) months from the date of issue.

The Company issued the Fee Shares on 10 September 2025 and the Completion Shares on 2 October 2025 (being the date on which Completion occurred under the Impact Agreement) utilising its existing Listing Rule 7.1 placement capacity.

A summary of the material terms of the Impact Agreement is set out in Schedule 2 of this Notice.

Resolutions 1 and 2 seek Shareholder ratification for the purposes of Listing Rule 7.4 for the issue of the Consideration Shares (being 3,125,000 Shares) to Impact in part consideration for the Earn-In, pursuant to the Impact Agreement.

1.2 Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that 12 month period.

The issue of the Consideration Shares does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the date of the issue.

1.3 Listing Rule 7.4

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under Listing Rule 7.1. Accordingly, the Company is seeking Shareholder ratification pursuant to Listing Rule 7.4 for the issue of the Consideration Shares.

1.4 Technical information required by Listing Rule 14.1A

If Resolutions 1 and 2 are passed, the issue will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue.

If Resolutions 1 and 2 are not passed, the issue will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue.

1.5 Technical information required by Listing Rules 7.4 and 7.5

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities were issued or the basis on which those persons were identified/selected	Impact Minerals Limited.
Number and class of Securities issued	3,125,000 Shares were issued on the following basis: (a) 250,000 Shares issued on 10 September 2025 utilising existing 7.1 placement capacity on (the subject of Resolution 1) (; and (b) 2,875,000 Shares issued on 2 October 2025 utilising the Company's existing Listing Rule 7.1 Capacity (the subject of Resolution 2).
Terms of Securities	The Consideration Shares were fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
Date(s) on or by which the Securities were issued.	The Fee Shares were issued on 10 September 2025 and the Completion Shares were issued on 2 October 2025.
Price or other consideration the Company received for the Securities	The Consideration Shares were issued at a nil issue price, as part consideration for the Earn-In.
Purpose of the issue, including the intended use of any funds raised by the issue	The purpose of the issue of the Consideration Shares was to satisfy part of the Company's obligations under the Impact Agreement.
Summary of material terms of agreement to issue	The Consideration Shares were issued under the Impact Agreement, a summary of the material terms of which is set out in Schedule 2.
Voting Exclusion Statement	A voting exclusion statement applies to Resolutions 1 and 2.
Compliance	The issue of Consideration Shares did not breach Listing Rule 7.1.

2. BACKGROUND TO RESOLUTIONS 3 TO 7

2.1 Entitlement Offer

As announced on 31 July 2025 (and as extended via the announcement on 26 August 2025), the Company undertook a pro-rata non-renounceable entitlement offer of one (1) Share for every three (3) Shares held by eligible Shareholders at an issue price of \$0.07 per Share, together with one (1) free-attaching Option (exercisable at \$0.14 each, and expiring on or before the date that is two (2) years from the date of issue)

(**Attaching Options**) for every three (3) Shares subscribed for and issued under the entitlement offer, to raise up to approximately \$2,032,900 (before costs) (**Entitlement Offer**).

The Entitlement Offer also included a shortfall offer (**Shortfall Offer**) to subscribe for entitlements not taken up by eligible Shareholders at an issue price of \$0.07 per Share, together with one (1) Attaching Option for every three (3) Shares subscribed and issued under the Shortfall Offer, being the same terms on which Securities are offered under the Entitlement Offer.

2.2 Underwriting Agreement

As detailed in the announcement dated 8 September 2025, the Company entered into an underwriting agreement with GBA Capital Pty Ltd (ACN 643 039 123) (**GBA Capital** or **Underwriter**) dated on or about 7 September 2025 (**Underwriting Agreement**) pursuant to which GBA Capital agreed to partially underwrite the Entitlement Offer up to the amount of \$1,200,000.06.

The Company also appointed GBA Capital to act as lead manager to the Entitlement Offer.

As part consideration for the underwriting obligation undertaken by GBA Capital pursuant to the Underwriting Agreement, the Company has agreed to issue to GBA Capital (or its nominee(s)), subject to Shareholder approval, 5,808,285 Options on the same terms as the Attaching Options, being that number of Options equal to:

- (a) 20% of the total number of Shares underwritten by GBA Capital; and
- (b) 20% of the maximum number of Shares that may be placed by GBA Capital under the Shortfall,

(together, the **Underwriting Fee Options**).

Accordingly, the Company seeks Shareholder approval for the issue of the Underwriting Fee Options to GBA Capital (or its nominee(s)) under Resolution 3.

A summary of the material terms of the Underwriting Agreement is set out in Schedule 3 of this Notice.

2.3 Applications Under the Entitlement Offer

The Company has agreed to satisfy the outstanding balance of amounts owing to its current board of Directors, Gavin Rezos, Brendan Borg and Maja McGuire, in unpaid Director fees for the period comprising 1 January 2025 to 31 July 2025 (**Accrued Director Fees**) by setting off the cost of subscriptions for their respective entitlements under the Entitlement Offer and, subject to Shareholder approval, the Shortfall Offer (as applicable), against the Accrued Director Fees at a deemed issue price of \$0.07 per Share (being the issue price under the Entitlement Offer) (**Director Fee Offset**).

The effect of the Director Fee Offset on the Accrued Director Fees is set out in the table below.

DIRECTOR	ENTITLEMENT UNDER ENTITLEMENT OFFER	DEEMED VALUE OF ENTITLEMENT UNDER ENTITLEMENT OFFER	ACCRUED DIRECTOR FEES – 1 JAN 2025 – 31 JULY 2025	BALANCE OF ENTITLEMENT VALUE TO BE PAID FOLLOWING DIRECTOR FEE OFFSET	BALANCE OF ACCRUED DIRECTOR FEES FOLLOWING DIRECTOR FEE OFFSET
Gavin Rezos	1,452,518 Shares	\$101,676.26	\$66,144.60	\$35,531.66	Nil
Brendan Borg	475,000 Shares	\$33,250.00	\$26,016.64	\$7,223.36	Nil
Maja McGuire	127,247 Shares	\$8,907.29	\$26,016.64	Nil	\$17,109.35

2.4 Shortfall Offer Set Off Against Debts Owed by the Company

The Company has agreed to apply the balance of Ms McGuire's Accrued Director Fees (being \$17,109.35) towards her subscription for up to 244,420 Shares and 81,474 Attaching Options (**Shortfall Securities**) under the Shortfall Offer (**Director Participation**), subject to Shareholder approval.

Resolution 4 seeks Shareholder approval for the issue of the Shortfall Securities (being 244,420 Shares and 81,474 Attaching Options) to Ms McGuire under the Director Participation.

In addition, the Company has agreed to satisfy part of the outstanding debt owing to GAM Company Pty Ltd (ACN 680 708 249) for loan fees payable by the Company in the amount of \$147,133 under a debt facility arrangement announced on 25 February 2025 through the issue of an aggregate of 2,101,901 Shares and 700,635 Attaching Options under the Shortfall Offer.

2.5 Top-up Placement

As announced on 16 September 2025, the Entitlement Offer raised approximately \$1,200,000 (before costs) as at its closing date of 12 September 2025, with a Shortfall Offer of approximately \$832,900.

The Company announced on 8 October 2025 that, working with GBA Capital, it had successfully placed all Securities under the Shortfall Offer. Following receipt of expressions of interest from sophisticated and professional investors (**Top-up Placement Participants**) to subscribe for additional Securities on the same terms as the Entitlement Offer (**Additional Subscriptions**), the Company has elected pursuant to the terms of the Underwriting Agreement to proceed with a placement (**Top-up Placement**) to the Top-up Placement Participants to raise approximately a further \$685,773 (before costs).

The Company issued 9,796,755 Shares under the Top-up Placement utilising its existing 7.1A placement capacity on 13 October 2025 (ratification of which is sought under Resolution 5) and the Company has agreed to issue 3,265,585 Attaching Options under the Top-up Placement subject to Shareholder approval (pursuant to Resolution 6) (together, the **Top-up Placement Securities**).

Pursuant to the terms of the Underwriting Agreement, in consideration for GBA Capital placing the Top-up Placement Securities, the Company has agreed to:

- (a) pay GBA Capital an additional placement fee equal to 6.0% of amounts raised under the Top-up Placement (\$41,146.38) (excluding GST) in immediately available funds; and
- (b) issue Options to GBA Capital (or its nominee(s)) in an amount equal to the number of Shares issued under the Top-up Placement divided by five (being 1,959,351 Options) (**Top-up Fee Options**), subject to Shareholder approval pursuant to Resolution 7.

2.6 Use of Funds

The funds raised under the Entitlement Offer (including the Shortfall Offer) and the Top-up Placement are intended to be applied towards toward Stage-1 earn-in commitments at the Commonwealth Project, including technical programs, drill preparation and initial exploration, with the balance to be directed towards the repayment of outstanding debt and interest (including by set-off as noted above), general and administrative expenses, exploration expenditure, working capital and expenses of both the Entitlement Offer and Top-up Placement.

3. RESOLUTION 3 – APPROVAL TO ISSUE UNDERWRITING FEE OPTIONS TO GBA CAPITAL

3.1 General

As set out in Section 2.2, Resolution 3 seeks Shareholder approval for the purposes of Listing Rule 7.1 for the issue of Underwriting Fee Options (being 5,808,285 Options) to GBA Capital (or its nominee(s)) pursuant to the Underwriting Agreement.

3.2 Listing Rule 7.1

A summary of Listing Rule 7.1 is set out in Section 1.2 above.

The proposed issue of Underwriting Fee Options falls within exception 17 of Listing Rule 7.2 which excludes from the restrictions in Listing Rules 7.1 and 7.1A an agreement to issue equity securities that is conditional on the holders of its ordinary securities approving the issue under Listing Rule 7.1 before the issue of Underwriting Fee Options is made. The proposed issue of Underwriting Fee Options therefore requires the approval of Shareholders under Listing Rule 7.1.

3.3 Technical information required by Listing Rule 14.1A

If Resolution 3 is passed, the Company will be able to proceed with the issue. In addition, the issue will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 3 is not passed, the Company will not be able to proceed with the issue of Underwriting Fee Options. As a result, the Company may be in breach of the Underwriting Agreement and will be required to pay the cash equivalent of the Underwriting Fee Options (based on a Black-Scholes value) within two (2) business days of the Meeting, which would deplete the Company's cash reserves.

3.4 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected	GBA Capital Pty Ltd (or its nominee(s)) and any sub-underwriters to the Entitlement Offer, who are not related parties of the Company.
Number of Securities and class to be issued	5,808,285 Underwriting Fee Options will be issued.
Terms of Securities	The Underwriting Fee Options will be issued on the terms and conditions set out in Schedule 1.
Date(s) on or by which the Securities will be issued	The Company expects to issue the Underwriting Fee Options within 5 Business Days of the Meeting. In any event, the Company will not issue any Underwriting Fee Options later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
Price or other consideration the Company will receive for the Securities	The Underwriting Fee Options will be issued at a nil issue price, as part consideration for the underwriting obligation undertaken by GBA Capital pursuant to the Underwriting Agreement.
Purpose of the issue, including the intended use of any funds raised by the issue	The purpose of the issue of Underwriting Fee Options is to part satisfy the Company's obligations under the Underwriting Agreement.
Summary of material terms of agreement to issue	The Underwriting Fee Options are being issued under the Underwriting Agreement, a summary of the material terms of which is set out in Schedule 3.
Voting exclusion statement	A voting exclusion statement applies to Resolution 3.

4. RESOLUTION 4 – APPROVAL TO ISSUE SHORTFALL SECURITIES TO RELATED PARTY – MAJA MCGUIRE

4.1 General

As set out in Section 2.4, Resolution 4 seeks Shareholder approval for the purposes of Listing Rule 10.11 for the issue the Shortfall Securities (being up to 244,420 Shares and 81,474 Attaching Options) to Ms McGuire (or her nominee(s)) pursuant to the Director Participation in the Shortfall Offer.

4.2 Chapter 2E of the Corporations Act

Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue constitutes giving a financial benefit and Ms McGuire is a related party of the Company by virtue of being a Director.

The Directors (other than Ms McGuire who has a material personal interest in the Resolution) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue because the Shortfall Securities will be issued to Ms McGuire (or her nominee(s)) on the same terms as Securities issued to non-related party participants in the capital raising and as such the giving of the financial benefit is on arm's length terms.

4.3 Listing Rule 10.11

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to:

- 10.11.1 a related party;
- 10.11.2 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the company;
- 10.11.3 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;
- 10.11.4 an associate of a person referred to in Listing Rules 10.11.1 to 10.11.3; or
- 10.11.5 a person whose relationship with the company or a person referred to in Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The issue falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

4.4 Technical information required by Listing Rule 14.1A

If Resolution 4 is passed, the Company will be able to proceed with the issue of Shortfall Securities to Ms McGuire (or her nominee(s)) pursuant to the Director Participation within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules) and will raise additional funds which will be used in the manner set out in Section 2.6. As approval pursuant to Listing Rule 7.1 is not required for the Ms McGuire's Director Participation (because approval is being obtained

under Listing Rule 10.11), the issue will not use up any of the Company's 15% annual placement capacity.

If Resolution 4 is not passed, the Company will not be able to proceed with the issue of Shortfall Securities to Ms McGuire (or her nominee(s)) pursuant to the Director Participation and the Company will be required to find alternative methods of satisfying the remaining outstanding balance of Ms McGuire's Accrued Director Fees, including through payment of funds from the Company's existing cash reserves.

4.5 Technical Information required by Listing Rule 10.13

REQUIRED INFORMATION	DETAILS
Name of the person to whom Securities will be issued	The Shortfall Securities will be issued to Ms McGuire (or her nominee(s)) pursuant to the Director Participation under the Shortfall Offer.
Categorisation under Listing Rule 10.11	Ms McGuire falls within the category set out in Listing Rule 10.11.1 as she is a related party of the Company by virtue of being a Director. Any nominee(s) of Ms McGuire who receive Shortfall Securities may constitute 'associates' for the purposes of Listing Rule 10.11.4.
Number of Securities and class to be issued	244,420 Shares and 81,474 Attaching Options will be issued.
Terms of Securities	The Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares. The Attaching Options will be issued on the terms and conditions set out in Schedule 1.
Date(s) on or by which the Securities will be issued	The Company expects to issue the Shortfall Securities to Ms McGuire (or her nominee(s)) pursuant to the Director Participation within 5 Business Days of the Meeting. In any event, the Company will not issue any Shortfall Securities to Ms McGuire (or her nominee(s)) pursuant to the Director Participation later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
Price or other consideration the Company will receive for the Securities	Nil monies are payable for the Shortfall Securities as the Shortfall Securities are issued for the Accrued Director Fees. The Shares will be issued at a deemed issue price of \$0.07 per Share, and the Attaching Options will be issued at a nil issue price as the Options will be issued free attaching to the Shares on a 1:3 basis.
Purpose of the issue, including the intended use of any funds raised by the issue	Refer to Section 2.6 for details of the proposed use of funds.
Summary of material terms of agreement to issue	The Shortfall Securities are being issued to Ms McGuire (or her nominee(s)) pursuant to the Director Participation, a summary of the material terms of which is set out in Section 2.4.
Voting exclusion statement	A voting exclusion statement applies to Resolution 4.

5. RESOLUTION 5 – RATIFICATION OF PRIOR ISSUE OF SHARES UNDER TOP-UP PLACEMENT

5.1 General

As set out in Section 2.5, Resolution 5 seeks Shareholder ratification for the purposes of Listing Rule 7.4 for the issue of 9,796,755 Shares at an issue price of \$0.07 per Share to raise approximately \$685,773 (before costs). The Shares were issued on 13 October 2025 pursuant to the Company's capacity under Listing Rule 7.1A.

5.2 Listing Rules 7.1 and 7.1A

A summary of Listing Rule 7.1 is set out in Section 1.2 above.

Under Listing Rule 7.1A however, an Eligible Entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%. The Company obtained this approval at its annual general meeting held on 29 May 2025.

The issue of does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 25% limit in Listing Rules 7.1 and 7.1A, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the date of the issue.

5.3 Listing Rule 7.4

A summary of Listing Rule 7.4 is set out in Section 1.3 above.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under Listing Rule 7.1. Accordingly, the Company is seeking Shareholder ratification pursuant to Listing Rule 7.4 for the issue.

5.4 Technical information required by Listing Rule 14.1A

If Resolution 5 is passed, the issue of Shares under the Top-up Placement will be excluded in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue.

If Resolution 5 is not passed, the issue will be included in calculating the Company's 10% limit in Listing Rule 7.1A, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue.

5.5 Technical information required by Listing Rules 7.4 and 7.5

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities were issued or the basis on which those persons were identified/selected	The Shares were issued to the Top-up Placement Participants. The Company confirms that no Material Persons were issued more than 1% of the issued capital of the Company.
Number and class of Securities issued	9,796,755 Shares were issued.
Terms of Securities	The Shares were fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
Date(s) on or by which the Securities were issued	13 October 2025.

REQUIRED INFORMATION	DETAILS
Price or other consideration the Company received for the Securities	\$0.07 per Share.
Purpose of the issue, including the intended use of any funds raised by the issue	Refer to Section 2.6 for details of the proposed use of funds.
Summary of material terms of agreement to issue	The Shares were not issued under an agreement.
Voting Exclusion Statement	A voting exclusion statement applies to Resolution 5.
Compliance	The issue of Shares under the Top-up Placement did not breach Listing Rule 7.1.

6. RESOLUTION 6 – APPROVAL TO ISSUE ATTACHING OPTIONS UNDER TOP-UP PLACEMENT

6.1 General

Resolution 6 seeks Shareholder approval for the purposes of Listing Rule 7.1 for the issue of 3,265,585 Attaching Options to the Top-up Placement Participants, being equal to one (1) Option for every three (3) Shares subscribed for under the Top-up Placement. The Options will be exercisable at \$0.14 each on or before two (2) years from the date of issue and otherwise on the terms and conditions set out in Schedule 1.

A summary of Listing Rule 7.1 is set out in Section 1.2 above.

The proposed issue of Attaching Options to the Top-up Placement Participants falls within exception 17 of Listing Rule 7.2. It therefore requires the approval of Shareholders under Listing Rule 7.1.

6.2 Technical information required by Listing Rule 14.1A

If Resolution 6 is passed, the Company will be able to proceed with the issue. In addition, the issue will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 6 is not passed, the Company will not be able to proceed with the issue of Attaching Options to the Top-up Placement Participants and the Company may be held to be in breach of the terms of the Top-up Placement, and could be required to satisfy its obligation to issue the Attaching Options by making payments from the Company's existing cash reserves.

6.3 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected	The Attaching Options will be issued to the Top-up Placement Participants. The Company confirms that no Material Persons were issued more than 1% of the issued capital of the Company.
Number of Securities and class to be issued	3,267,734 Attaching Options will be issued under the Top-up Placement.

REQUIRED INFORMATION	DETAILS
Terms of Securities	The Attaching Options will be issued on the terms and conditions set out in Schedule 1.
Date(s) on or by which the Securities will be issued	The Company expects to issue the Attaching Options within 5 Business Days of the Meeting. In any event, the Company will not issue any Attaching Options later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
Price or other consideration the Company will receive for the Securities	The Attaching Options will be issued at a nil issue price, free attaching to the Shares issued to the Top-up Placement Participants under the Top-up Placement on a 1:3 basis. The Attaching Options issued under the Top-up Placement will be exercisable at \$0.14 each.
Purpose of the issue, including the intended use of any funds raised by the issue	Refer to Section 2.6 for details of the proposed use of funds.
Summary of material terms of agreement to issue	The Shares were not issued under an agreement.
Voting exclusion statement	A voting exclusion statement applies to Resolution 6.

7. RESOLUTION 7 – APPROVAL TO ISSUE TOP-UP FEE OPTIONS TO GBA CAPITAL

7.1 General

As set out in Section 2.5, Resolution 7 seeks Shareholder approval for the purposes of Listing Rule 7.1 for the issue of Top-up Fee Options (being 1,959,351 Options) to GBA Capital (or its nominee(s)) pursuant to the Underwriting Agreement.

7.2 Listing Rule 7.1

A summary of Listing Rule 7.1 is set out in Section 1.2 above.

The proposed issue of Top-up Fee Options falls within exception 17 of Listing Rule 7.2 which excludes from the restrictions in Listing Rules 7.1 and 7.1A an agreement to issue equity securities that is conditional on the holders of its ordinary securities approving the issue under Listing Rule 7.1 before the issue of Top-up Fee Options is made. The proposed issue of Top-up Fee Options therefore requires the approval of Shareholders under Listing Rule 7.1.

7.3 Technical information required by Listing Rule 14.1A

If Resolution 7 is passed, the Company will be able to proceed with the issue of Top-up Fee Options. In addition, the issue will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 7 is not passed, the Company will not be able to proceed with the issue of Top-up Fee Options. As a result, the Company may be in breach of the Underwriting Agreement and will be required to pay the cash equivalent of the Top-up Fee Options (based on a Black-Scholes value) within two (2) business days of the Meeting, which would deplete the Company's cash reserves.

7.4 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected	GBA Capital Pty Ltd (or its nominee(s)).
Number of Securities and class to be issued	1,959,351 Top-up Fee Options will be issued.
Terms of Securities	The Top-up Fee Options will be issued on the terms and conditions set out in Schedule 1.
Date(s) on or by which the Securities will be issued	The Company expects to issue the Top-up Fee Options within 5 Business Days of the Meeting. In any event, the Company will not issue any Top-up Fee Options later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
Price or other consideration the Company will receive for the Securities	The Top-up Fee Options will be issued at a nil issue price, as part consideration for GBA Capital placing the Top-up Placement Securities under the Top-up Placement.
Purpose of the issue, including the intended use of any funds raised by the issue	The purpose of the issue of Top-up Fee Options is to satisfy the Company's obligations under the Underwriting Agreement.
Summary of material terms of agreement to issue	The Top-up Fee Options are being issued under the Underwriting Agreement, a summary of the material terms of which is set out in Schedule 3.
Voting exclusion statement	A voting exclusion statement applies to Resolution 7.

8. RESOLUTION 8 – APPROVAL TO ISSUE OPTIONS TO AT CAPITAL EQUITY PTY LTD

8.1 General

On 25 July 2025, the Company entered into an investor relations agreement (**Investor Relations Agreement**) with AT Capital Equity Pty Ltd (ACN 647 482 086) (**AT Capital**), pursuant to which AT Capital has agreed to perform the following services:

- (a) promote the Company within its network, including email communications expressing its views on the Company's value and potential;
- (b) participate in meeting with brokers and other financial professionals in its network to promote the Company's stock;
- (c) leverage its expertise to better communicate information in a manner that would highlight the Company's achievements and value; and
- (d) promote on-market buying of the Company's Shares from investors in its network,

(together, the **Investor Relations Services**), for a period of twelve (12) months commencing on and from 25 July 2025.

In consideration for providing the Investor Relations Services, the Company agreed to issue, subject to Shareholder approval, 1,250,000 Options exercisable at \$0.12 on or before two (2) years from the date of issue (**Advisor Options**) to AT Capital (or its nominee(s)) pursuant to the Investor Relations Agreement.

The Investor Relations Agreement otherwise contains provisions considered standard for an agreement of its nature.

Resolution 8 seeks Shareholder approval for the issue of Advisor Options to AT Capital (or its nominee(s)).

8.2 Listing Rule 7.1

A summary of Listing Rule 7.1 is set out in Section 1.2 above.

The proposed issue of the Advisor Options falls within exception 17 of Listing Rule 7.2. Under Listing Rule 7.2 (Exception 17), if the issue of securities is subject to prior shareholder approval, it does not count toward the 15% placement limit set by Listing Rule 7.1. The proposed issue of the Advisor Options therefore requires the approval of Shareholders under Listing Rule 7.1.

8.3 Technical information required by Listing Rule 14.1A

If Resolution 8 is passed, the Company will be able to proceed with the issue of the Advisor Options. In addition, the issue of the Advisor Options will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 8 is not passed, the Company will not be able to proceed with the issue of the Advisor Options and the Company may be required to find alternative methods by which to satisfy its obligations under the Investor Relations Agreement, including through payment of funds from the Company's existing cash reserves.

8.4 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected	AT Capital (or its nominee(s)).
Number of Securities and class to be issued	1,250,000 Advisor Options will be issued.
Terms of Securities	The Advisor Options will be issued on the terms and conditions set out in Schedule 1.
Date(s) on or by which the Securities will be issued	The Company expects to issue the Advisor Options within 5 Business Days of the Meeting. In any event, the Company will not issue the Advisor Options later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
Price or other consideration the Company will receive for the Securities	The Advisor Options will be issued at a nil issue price as consideration for Investor Relations Services provided by AT Capital.
Purpose of the issue, including the intended use of any funds raised by the issue	The purpose of the issue of the Advisor Options is to satisfy the Company's obligations under the Investor Relations Agreement.
Summary of material terms of agreement to issue	The Advisor Options are being issued under the Investor Relations Agreement, a summary of the material terms of which is set out in Section 8.1.
Voting exclusion statement	A voting exclusion statement applies to Resolution 8.

9. RESOLUTIONS 9 TO 11 – APPROVAL TO ISSUE PERFORMANCE RIGHTS TO RELATED PARTIES

9.1 General

These Resolutions seek Shareholder approval for the purposes of Chapter 2E of the Corporations Act and Listing Rule 10.11 for the issue of up to an aggregate of 15,000,000 Performance Rights to Mr Gavin Rezos, Mr Brendan Borg and Ms Maja McGuire (or their respective nominees) on the terms and conditions set out below.

Further details in respect of the Performance Rights proposed to be issued are set out in the table below.

CLASS	QUANTUM	RECIPIENT	RESOLUTION	VESTING CONDITION	EXPIRY DATE
A	2,000,000	Gavin Rezos	9	The market capitalisation of the Company exceeding a value of \$13.5 million measured over a 5-day volume weighted average price (VWAP) of the Company's Shares..	The date that is three (3) years from the grant of the Performance Rights.
	1,500,000	Brendan Borg	10		
	1,500,000	Maja McGuire	11		
B	2,000,000	Gavin Rezos	9	The market capitalisation of the Company exceeding a value of \$16.0 million measured over a 5-day VWAP of the Company's Shares..	
	1,500,000	Brendan Borg	10		
	1,500,000	Maja McGuire	11		
C	2,000,000	Gavin Rezos	9	The market capitalisation of the Company exceeding a value of \$18.0 million measured over a 5-day VWAP of the Company's Shares.	
	1,500,000	Brendan Borg	10		
	1,500,000	Maja McGuire	11		

9.2 Director Recommendation

Each Director has a material personal interest in the outcome of Resolutions 9 to 11 on the basis that all of the Directors (or their nominee(s)) are to be issued Performance Rights should these Resolutions be passed. For this reason, the Directors do not believe that it is appropriate to make a recommendation on these Resolutions.

9.3 Chapter 2E of the Corporations Act

A summary of Chapter 2E of the Corporations Act is set out in Section 4.2 above.

The issue of Performance Rights constitutes giving a financial benefit and each of the proposed recipients is a related party of the Company by virtue of being a Director.

As Performance Rights are proposed to be issued to all of the Directors, the Directors are unable to form a quorum to consider whether one of the exceptions set out in sections 210 to 216 of the Corporations Act applies to the issue. Accordingly, Shareholder approval for the issue is sought in accordance with Chapter 2E of the Corporations Act.

9.4 Listing Rule 10.11

A summary of Listing Rule 10.11 is set out in Section 4.3 above.

The issue of Performance Rights falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

9.5 Technical information required by Listing Rule 14.1A

If Resolutions 9 to 11 are passed, the Company will be able to proceed with the issue within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules). As approval pursuant to Listing Rule 7.1 is not required for the issue (because approval is being obtained under Listing Rule 10.11), the issue will not use up any of the Company's 15% annual placement capacity.

If Resolutions 9 to 11 are not passed, the Company will not be able to proceed with the issue of Performance Rights to the Directors.

9.6 Technical Information required by Listing Rule 10.13 and section 219 of the Corporations Act

REQUIRED INFORMATION	DETAILS
Name of the persons to whom Securities will be issued	The Directors in the proportions set out in Section 9.1 above.
Categorisation under Listing Rule 10.11	Each of the proposed recipients falls within the category set out in Listing Rule 10.11.1 as they are a related party of the Company by virtue of being a Director. Any nominee(s) of the proposed recipients who receive Performance Rights may constitute 'associates' for the purposes of Listing Rule 10.11.4.
Number of Securities and class to be issued	The maximum number of Performance Rights to be issued (being the nature of the financial benefit proposed to be given) is 15,000,000 which will be allocated are set out in the table included at Section 9.1 above.
Terms of Securities	The Performance Rights will be issued to the Directors on the terms and conditions set out in Schedule 4.
Date(s) on or by which the Securities will be issued	The Company expects to issue the Performance Rights to the Directors within 5 Business Days of the Meeting. In any event, the Company will not issue any Performance Rights to the Directors later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
Price or other consideration the Company will receive for the Securities	The Performance Rights will be issued to the Directors at a nil issue price.
Purpose of the issue, including the intended use of any funds raised by the issue	The purpose of the issue of Performance Rights to the Directors is to provide a performance linked incentive component in the remuneration package for the proposed recipients to align the interests of the proposed recipients with those of Shareholders, to motivate and reward the performance of the proposed recipients in their roles as Directors and to provide a cost effective way from the Company to remunerate the proposed recipients, which will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to the proposed recipients.
Consideration of type of Security to be issued	The Company has agreed to issue the Performance Rights for the following reasons: (a) the issue of the Performance Rights has no immediate dilutionary impact on Shareholders;

REQUIRED INFORMATION	DETAILS												
	(b) the issue of Performance Rights to the Directors (or their respective nominees) will align their interests with those of Shareholders; (c) the issue is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to the Directors; and (d) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Performance Rights to the Directors on the terms proposed.												
Consideration of quantum of Securities to be issued	The number of Performance Rights to be issued to the Directors has been determined based upon a consideration of: (a) current market standards and/or practices of other ASX listed companies of a similar size and stage of development to the Company; (b) the remuneration of the Directors; and (c) incentives to attract and ensure continuity of service/retain the service of the proposed recipients who have appropriate knowledge and expertise, while maintaining the Company's cash reserves. The Company does not consider that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Performance Rights to the Directors upon the terms proposed.												
Remuneration	The total remuneration package for each of the Directors for the previous financial year and the proposed total remuneration package for the current financial year are set out below: <table><tr><th>RELATED PARTY</th><th>CURRENT FINANCIAL YEAR ENDING 31 DECEMBER 2025</th><th>PREVIOUS FINANCIAL YEAR ENDED 31 DECEMBER 2024</th></tr><tr><td>Gavin Rezos</td><td>\$435,182.25¹</td><td>\$97,344⁴</td></tr><tr><td>Brendan Borg</td><td>\$292,165²</td><td>\$38,938⁴</td></tr><tr><td>Maja McGuire</td><td>\$292,165²</td><td>\$43,134⁴</td></tr></table> Notes: 1. Comprising Directors' salary of \$87,500, a superannuation payment of \$10,281.25 and share-based payments of \$337,401, being the value of the Performance Rights. 2. Comprising Directors' salary of \$35,000, a superannuation payment of \$4,112.50 and share-based payments of \$253,052, being the value of the Performance Rights. 3. Refer to the Company's Annual Report for the year ended 31 December 2024 for further details.	RELATED PARTY	CURRENT FINANCIAL YEAR ENDING 31 DECEMBER 2025	PREVIOUS FINANCIAL YEAR ENDED 31 DECEMBER 2024	Gavin Rezos	\$435,182.25 ¹	\$97,344 ⁴	Brendan Borg	\$292,165 ²	\$38,938 ⁴	Maja McGuire	\$292,165 ²	\$43,134 ⁴
RELATED PARTY	CURRENT FINANCIAL YEAR ENDING 31 DECEMBER 2025	PREVIOUS FINANCIAL YEAR ENDED 31 DECEMBER 2024											
Gavin Rezos	\$435,182.25 ¹	\$97,344 ⁴											
Brendan Borg	\$292,165 ²	\$38,938 ⁴											
Maja McGuire	\$292,165 ²	\$43,134 ⁴											
Valuation	The value of the Performance Rights and the pricing methodology is set out in Schedule 5.												
Summary of material terms of agreement to issue	The Performance Rights are not being issued to the Directors under an agreement.												

REQUIRED INFORMATION	DETAILS																								
Interest in Securities	The relevant interests of the Directors in Securities as at the date of this Notice and following completion of the issue are set out below:																								
	As at the date of this Notice																								
	<table><tr><th>RELATED PARTY</th><th>SHARES¹</th><th>OPTIONS</th><th>PERFORMANCE RIGHTS</th><th>UNDILUTED</th><th>FULLY DILUTED</th></tr><tr><td>Gavin Rezos</td><td>5,810,070²</td><td>1,984,174⁵</td><td>Nil</td><td>5.41%</td><td>6.42%</td></tr><tr><td>Brendan Borg</td><td>1,900,000³</td><td>1,158,334⁶</td><td>Nil</td><td>1.77%</td><td>2.52%</td></tr><tr><td>Maja McGuire</td><td>508,986⁴</td><td>1,042,416⁷</td><td>Nil</td><td>0.47%</td><td>1.28%</td></tr></table>	RELATED PARTY	SHARES ¹	OPTIONS	PERFORMANCE RIGHTS	UNDILUTED	FULLY DILUTED	Gavin Rezos	5,810,070 ²	1,984,174 ⁵	Nil	5.41%	6.42%	Brendan Borg	1,900,000 ³	1,158,334 ⁶	Nil	1.77%	2.52%	Maja McGuire	508,986 ⁴	1,042,416 ⁷	Nil	0.47%	1.28%
	RELATED PARTY	SHARES ¹	OPTIONS	PERFORMANCE RIGHTS	UNDILUTED	FULLY DILUTED																			
	Gavin Rezos	5,810,070 ²	1,984,174 ⁵	Nil	5.41%	6.42%																			
Brendan Borg	1,900,000 ³	1,158,334 ⁶	Nil	1.77%	2.52%																				
Maja McGuire	508,986 ⁴	1,042,416 ⁷	Nil	0.47%	1.28%																				
Post issue of Performance Rights to the Directors pursuant to Resolutions 9 to 11																									
<table><tr><th>RELATED PARTY</th><th>SHARES¹</th><th>OPTIONS</th><th>PERFORMANCE RIGHTS</th><th>UNDILUTED</th><th>FULLY DILUTED</th></tr><tr><td>Gavin Rezos</td><td>5,810,070³</td><td>1,984,174⁶</td><td>6,000,000</td><td>5.41%</td><td>10.11%</td></tr><tr><td>Brendan Borg</td><td>1,900,000⁴</td><td>1,158,334⁷</td><td>4,500,000</td><td>1.77%</td><td>5.54%</td></tr><tr><td>Maja McGuire²</td><td>508,986⁵</td><td>1,042,416⁸</td><td>4,500,000</td><td>0.47%</td><td>4.44%</td></tr></table>	RELATED PARTY	SHARES ¹	OPTIONS	PERFORMANCE RIGHTS	UNDILUTED	FULLY DILUTED	Gavin Rezos	5,810,070 ³	1,984,174 ⁶	6,000,000	5.41%	10.11%	Brendan Borg	1,900,000 ⁴	1,158,334 ⁷	4,500,000	1.77%	5.54%	Maja McGuire ²	508,986 ⁵	1,042,416 ⁸	4,500,000	0.47%	4.44%	
RELATED PARTY	SHARES ¹	OPTIONS	PERFORMANCE RIGHTS	UNDILUTED	FULLY DILUTED																				
Gavin Rezos	5,810,070 ³	1,984,174 ⁶	6,000,000	5.41%	10.11%																				
Brendan Borg	1,900,000 ⁴	1,158,334 ⁷	4,500,000	1.77%	5.54%																				
Maja McGuire ²	508,986 ⁵	1,042,416 ⁸	4,500,000	0.47%	4.44%																				
	Notes: 1. Fully paid ordinary shares in the capital of the Company (ASX: KNI). 2. Excluding the Shortfall Securities proposed to be issued to Ms Maja McGuire pursuant to the Director Participation in the Shortfall Offer (the subject of Resolution 4). 3. Comprising: (a) 5,543,403 Shares held indirectly through Vivien Enterprises Pte Ltd; and (b) 266,667 Shares held indirectly through Floreant Ambo Pty Ltd. 4. Comprising: (a) 666,667 Shares held jointly with Mrs Erin Borg; and (b) 1,233,333 Shares held indirectly through Borg Geoscience Pty Ltd. 5. Comprising: (a) 28,986 Shares held directly; and (b) 480,000 Shares held indirectly through Maja McGuire <Scaraf A/C>. 6. Comprising: (a) 461,951 Shares held indirectly through Vivien Enterprises Pte Ltd; (b) 750,000 unquoted Options exercisable at \$0.69 each and expiring on or before 11 May 2027 held indirectly through Vivien Enterprises Pte Ltd; (c) 750,000 unquoted Options exercisable at \$0.921 each and expiring on or before 11 May 2027 held indirectly through Vivien Enterprises Pte Ltd; (d) 22,223 unquoted Options exercisable at \$0.14 each and expiring on or before 22 September 2027 held indirectly through Floreant Ambo Pty Ltd. 7. Comprising: (a) 55,556 unquoted Options exercisable at \$0.14 each and expiring on or before 22 September 2027 held jointly with Mrs Erin Borg; (b) 500,000 unquoted Options exercisable at \$0.69 each and expiring on or before 11 May 2027 held indirectly through Maja McGuire <Scaraf A/C>; and (c) 500,000 unquoted Options exercisable at \$0.921 each and expiring on or before 11 May 2027 held indirectly through Maja McGuire																								

REQUIRED INFORMATION	DETAILS												
	<Scaraf A/C>. 8. Comprising: (a) 2,416 unquoted Options exercisable at \$0.14 each and expiring on or before 22 September 2027 held directly; (b) 40,000 unquoted Options exercisable at \$0.14 each and expiring on or before 22 September 2027 held indirectly through Maja McGuire <Scaraf A/C>; (c) 500,000 unquoted Options exercisable at \$0.69 each and expiring on or before 11 May 2027 held indirectly through Maja McGuire <Scaraf A/C>; and (d) 500,000 unquoted Options exercisable at \$0.921 each and expiring on or before 11 May 2027 held indirectly through Maja McGuire <Scaraf A/C>.												
Dilution	If the Performance Rights issued under Resolutions 9 to 11 are exercised, a total of 15,000,000 Shares would be issued. This will increase the number of Shares on issue from 107,389,742 (being the total number of Shares on issue as at the date of this Notice) to 122,389,742 (assuming that no Shares are issued and no other convertible securities vest or are exercised) with the effect that the shareholding of existing Shareholders would be diluted by an aggregate of 13.97%, comprising 5.59% by Mr Rezos, 4.19% by Mr Borg and 4.19% by Ms McGuire.												
Trading history	The trading history of the Shares on ASX in the 12 months before the date of this Notice is set out below: <table><tr><th></th><th>PRICE</th><th>DATE</th></tr><tr><td>Highest</td><td>\$0.25</td><td>1 November 2024</td></tr><tr><td>Lowest</td><td>\$0.065</td><td>25 September 2025</td></tr><tr><td>Last</td><td>\$0.069</td><td>27 October 2025</td></tr></table>		PRICE	DATE	Highest	\$0.25	1 November 2024	Lowest	\$0.065	25 September 2025	Last	\$0.069	27 October 2025
	PRICE	DATE											
Highest	\$0.25	1 November 2024											
Lowest	\$0.065	25 September 2025											
Last	\$0.069	27 October 2025											
Other information	The Board is not aware of any other information that is reasonably required by Shareholders to allow them to decide whether it is in the best interests of the Company to pass Resolutions 9 to 11.												
Voting exclusion statements	Voting exclusion statements apply to Resolutions 9 to 11.												
Voting prohibition statements	Voting prohibition statements apply to Resolutions 9 to 11.												

GLOSSARY

\$ means Australian dollars.

Accrued Director Fees has the meaning given to it in Section 2.3.

Advisor Options has the meaning given to it in Section 8.1, and on the terms and conditions set out in Schedule 1.

Additional Subscriptions has the meaning given in Section 2.5.

Attaching Options has the meaning given to it in Section 2.1, and on the terms and conditions set out in Schedule 1.

AT Capital means AT Capital Equity Pty Ltd (ACN 647 482 086).

ASIC means the Australian Securities & Investments Commission.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

Board means the current board of directors of the Company.

Business Day means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

Chair means the chair of the Meeting.

Company means Kuniko Limited (ACN 619 314 055).

Completion Shares has the meaning given in Section 1.1.

Consideration Shares has the meaning given in Section 1.1.

Constitution means the Company's constitution.

Corporations Act means the *Corporations Act 2001* (Cth).

Director Fee Offset has the meaning given in Section 2.3.

Director Participation has the meaning given to it in Section 2.4.

Directors means the current directors of the Company.

Entitlement Offer has the meaning given to it in Section 2.1.

Endeavour means Endeavour Minerals Pty Ltd (ACN 063 725 708).

Explanatory Statement means the explanatory statement accompanying the Notice.

Fee Shares has the meaning given in Section 1.1.

GBA Capital or the **Underwriter** means GBA Capital Pty Ltd (ACN 643 039 123) (Corporate Authorised Representative of AFSL 544680).

Impact means Impact Minerals Limited (ACN 119 062 261) (ASX:IPT).

Impact Agreement has the meaning given in Section 1.1.

Investor Relations Agreement has the meaning given to it in Section 8.1.

Investor Relations Services has the meaning given to it in Section 8.1.

Listing Rules means the Listing Rules of ASX.

Meeting means the meeting convened by the Notice.

Notice means this notice of meeting including the Explanatory Statement and the Proxy Form.

Option means an option to acquire a Share.

Optionholder means a holder of an Option.

Performance Rights means Securities convertible into Shares, subject to certain vesting conditions.

Proxy Form means the proxy form accompanying the Notice.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Section means a section of the Explanatory Statement.

Security means a Share or Option (as applicable).

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Shortfall Offer has the meaning given to it in Section 2.1.

Shortfall Securities has the meaning given to it in Section 2.4.

Top-up Fee Options has the meaning given in Section 2.5.

Top-up Placement has the meaning given in Section 2.5.

Top-up Placement Participants has the meaning given in Section 2.5.

Top-up Placement Securities has the meaning given in Section 2.5.

Underwriting Agreement has the meaning given to it in Section 2.2.

Underwriting Fee Options has the meaning given to it in Section 2.2, and on the terms and conditions set out in Schedule 1.

WST means Western Standard Time as observed in Perth, Western Australia.

SCHEDULE 1 – TERMS AND CONDITIONS OF THE ATTACHING OPTIONS, UNDERWRITING FEE OPTIONS, TOP-UP FEE OPTIONS AND ADVISOR OPTIONS

(a) **Entitlement**

Each Option entitles the holder to subscribe for one Share upon exercise of the Option.

(b) **Exercise Price**

The amount payable upon exercise of each:

- (i) **Attaching Option, Underwriting Fee Option and Top-up Fee Option:** \$0.14; and
 - (ii) **Advisor Option:** \$0.12,
- (each an **Exercise Price**).

(c) **Expiry Date**

Each Option will expire at 5:00pm (WST) on or before two (2) years from the date of issue (**Expiry Date**).

An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.

(d) **Exercise Period**

The Options are exercisable at any time on or prior to the Expiry Date (**Exercise Period**).

(e) **Notice of Exercise**

The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.

(f) **Exercise Date**

A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).

(g) **Timing of issue of Shares on exercise**

Within five Business Days after the Exercise Date, the Company will:

- (i) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Notice of Exercise and for which cleared funds have been received by the Company;
- (ii) if required, give ASX a notice that complies with section 708A(5) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and
- (iii) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.

If a notice delivered under (g)(ii) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

(h) **Shares issued on exercise**

Shares issued on exercise of the Options rank equally with the then issued shares of the Company.

(i) **Reconstruction of capital**

If at any time the issued capital of the Company is reconstructed, all rights of an Optionholder are to be changed in a manner consistent with the Corporations Act and the Listing Rules at the time of the reconstruction.

(j) **Participation in new issues**

There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.

(k) **Change in exercise price**

An Option does not confer the right to a change in Exercise Price or a change in the number of underlying securities over which the Option can be exercised.

(l) **Transferability**

The Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.

SCHEDULE 2 - SUMMARY OF THE MATERIAL TERMS AND CONDITIONS OF THE IMPACT AGREEMENT

Consideration	In consideration for the Earn-In, the Company agrees to issue: (a) 250,000 Shares to Impact (or its nominee(s)) within 5 business days of the execution date of the Impact Agreement; and (b) 2,875,000 Shares to Impact (or its nominee(s)), subject to, and upon completion.
Conditions precedent	The commencement of the Earn-In is conditional upon the satisfaction (or waiver) of the following conditions: (a) Due diligence by the Company: completion of due diligence by the Company on the Commonwealth Project (including technical, legal, financial, environmental and title), to the absolute sole satisfaction of the Company; and (b) Regulatory approvals: the parties to the Impact Agreement obtaining all necessary corporate, governmental and regulatory approvals, consents or waivers pursuant to the Listing Rules (including ASX confirmation that Chapter 11 of the Listing Rules does not apply to the Impact Agreement), the Corporations Act, the Mining Act (including the Minister responsible for the Mining Act) and any other applicable laws, to allow the parties to the Impact Agreement to lawfully complete the matters set out in the Impact Agreement, (together, the Conditions).
Stage 1 Interest	Subject to the satisfaction or waiver of the Conditions, the Company may earn an initial 51% interest in the Commonwealth Project (Stage 1 Interest) by expending \$1,500,000 on qualifying expenditure on the Commonwealth Project (which includes expending a minimum of \$50,000 on each of the four tenements prior to their expiry dates, such work must include mapping, geochemistry and surface work) within 24 months from completion occurring under the Impact Agreement (Stage 1 Obligation). If, by the end of the period, the Company has not satisfied the Stage 1 Obligation, then the Company will be entitled to a 60-day period to cure the shortfall of the Stage 1 Obligation.
Stage 2 Interest	Subject to the Company earning the Stage 1 Interest, the Company may earn an additional 19% interest in the Commonwealth Project (70% overall) (Stage 2 Interest) by expending an additional \$1,500,000 on qualifying expenditure on the Commonwealth Project in the period commencing on the satisfaction of the Stage 1 Obligation and up until the date that is 24 months after satisfaction of the Stage 1 Obligation (Stage 2 Obligation). If, by the end of the period, the Company has not satisfied the Stage 2 Obligation, then the Company will be entitled to a 60-day period to cure the shortfall of the Stage 2 Obligation, failing which the Company's interest in the Commonwealth Project will be reduced to 49%.
Formation of Joint Venture	On and from the date that the Company satisfies the Stage 2 Obligation, a joint venture between the Company, Impact and Impact's wholly-owned subsidiary, Endeavour (Joint Venture) will be automatically formed in respect to the Commonwealth Project and the terms of the Joint Venture set out in the Impact Agreement will apply and be binding on the parties. From the commencement date of the Joint Venture between the parties, the Company will have a 70% interest in, and Impact will have a 30% interest in, the Joint Venture. On and from the commencement date of the Joint Venture until a

	feasibility study has been completed and a decision to mine is resolved, the Company agrees to solely fund all costs incurred in connection with the activities of the Joint Venture and to free carry Impact's interest in the Joint Venture.
Conversion to Royalty	If either party's interest in the joint venture is diluted to less than 10%, that party will be deemed to have elected to cease participating in the joint venture and convert its interest to a 2.0% net smelter return royalty over the Commonwealth Project. The Company has the right to buy back 50% of the net smelter return royalty from the diluting party for \$5,000,000 within 24 months of first production on any tenement on the Commonwealth Project.
Other	The Impact Agreement otherwise contains provisions considered standard for an agreement of its nature (including representations and warranties and confidentiality provisions)."

SCHEDULE 3 - SUMMARY OF THE MATERIAL TERMS AND CONDITIONS OF THE UNDERWRITING AGREEMENT

Fees	As consideration for the underwriting obligation undertaken by the Underwriter pursuant to the Underwriting Agreement, the Company has agreed to: (a) pay the Underwriter an underwriting fee equal to 6% of 1,200,000.06; (b) pay the Underwriter a shortfall placement fee equal to 6% of the value of subscriptions for Shares placed by GBA Capital under the Shortfall Offer (if any); and (c) issue the Underwriter (or its nominee(s)) the Underwriting Fee Options. The issue of the Underwriting Fee Options is subject to Shareholder approval at the Meeting. All sub-underwriting fees and selling fees will be paid by the Underwriter. In addition to the fees payable to the Underwriter as set out above, the Company will reimburse the Underwriter's reasonable out-of-pocket expenses (including any applicable GST) incurred in connection with the Entitlement Offer provided that the aggregate of all costs and expenses does not exceed \$15,000 (without the prior written consent of the Company).
Additional Subscriptions	The Underwriter will be permitted to seek expressions of interest from sophisticated and professional investors for Additional Subscriptions. Having been presented with Additional Subscriptions, the Company may notify the Underwriter of its election to place the Additional Subscriptions under a Top-up Placement utilising its available placement capacity under Listing Rules 7.1 and 7.1A (or by alternative means if agreed by the Underwriter). As consideration for placing Additional Subscriptions under the Top-up Placement, the Company has agreed to: (a) pay the Underwriter an additional placement fee equal to 6.0% of the amounts raised under the Top-up Placement (excluding GST) in immediately available funds; and (b) issue Top-up Fee Options to the Underwriter (or its nominee(s)) in an amount equal to the number of Shares issued under the Top-up Placement divided by five, subject to Shareholder approval at the Meeting. If the Company does not obtain Shareholder approval at the Meeting, the Company will pay the Underwriter the cash equivalent of the Top-up Fee Options (based on a Black-Scholes value) within 2 Business Days of the Meeting.
60-day Moratorium	The Company must ensure that from the lodgement date of the supplementary prospectus dated 8 September 2025 (Supplementary Prospectus) supplementary to the prospectus dated 31 July 2025 (Prospectus) until the date being sixty (60) days after the liability of the Underwriter under the Underwriting Agreement terminates or the issue of the 17,142,858 Shares (Underwritten Shares) and 5,714,286 Attaching Options (together, the Underwritten Securities), whichever is the earlier: (a) the Company will not, without the prior written consent of the Underwriter (which shall not be unreasonably withheld) or as otherwise contemplated in the Underwriting Agreement or in the Entitlement Offer, Impact Agreement or otherwise advised to the Underwriter before the date of the Underwriting Agreement: (i) issue, or agree or offer to issue, any equity securities, other than in connection with the Entitlement Offer,

	pursuant to the exercise or conversion of any equity securities, pursuant to an employee incentive scheme or pursuant to any distribution reinvestment plan; (ii) enter into any agreement or commitment which is material in the context of the Company; (iii) amend its constitution or any other constituent document except as required by ASX to comply with the Listing Rules, or as required by the Corporations Act; (iv) pass or take any steps to pass a resolution under section 260B of the Corporations Act; (v) dispose or agree to dispose of the whole or a substantial part of its business or property; or (vi) charge or agree to charge the whole or a substantial part of its business or property; and (b) neither the Company or a subsidiary of the Company (Relevant Company) proposes or activates any share buy-back scheme or arrangement or issues or agrees to issue, or indicates in any way that it will or might issue, or grants an option to subscribe for any shares or other securities or securities convertible into shares or other securities except: (i) as referred to in the Underwriting Agreement or the Prospectus; or (ii) with the prior written consent of the Underwriter.
Termination Events	The obligation of the Underwriter to underwrite the Entitlement Offer is subject to certain events of termination. The Underwriter may immediately terminate the Underwriting Agreement by notice if one of the following termination events occurs or has occurred prior to issue of the new Shares under the Entitlement Offer: (a) indices fall: the S&P ASX 200 Index is at any time after the date of the Underwriting Agreement and for at least three consecutive Business Days, 10% or more below its respective level as at the close of business on the Business Day prior to the date of the Underwriting Agreement; or (b) Share price: the volume weighted average price of the Shares as traded on ASX over any three (3) consecutive trading day period after the date of lodgement with ASIC of the Supplementary Prospectus is equal to or less than \$0.055; or (c) Prospectus: the Company does not lodge the Supplementary Prospectus on the agreed lodgement date or the Supplementary Prospectus or the Entitlement Offer is withdrawn by the Company; or (d) Supplementary Prospectus: (i) the Underwriter, having elected not to exercise its right to terminate its obligations under the Underwriting Agreement as a result of an occurrence as described in clause 11.2(q)(v) of the Underwriting Agreement, forms the view on reasonable grounds that a supplementary prospectus should be lodged with ASIC for any of the reasons referred to in section 719 of the Corporations Act and the Company fails to lodge a supplementary prospectus in such form and content and within such time as the Underwriter may reasonably require; or (ii) the Company lodges a supplementary prospectus without the prior written agreement of the Underwriter;

or

- (e) **non-compliance with disclosure requirements:** it transpires that the Prospectus does not contain all the information required by the Corporations Act or ASIC Regulatory Guide 228; or
- (f) **misleading Prospectus:** it transpires that there is a statement in the Prospectus that is misleading or deceptive or likely to mislead or deceive in any material respect, or that there is an omission from the Prospectus (having regard to the provisions of sections 711, 713 and 716 of the Corporations Act) or if any statement in the Prospectus becomes misleading or deceptive or likely to mislead or deceive in any material respect or if the issue of the Prospectus is or becomes misleading or deceptive or likely to mislead or deceive; or
- (g) **proceedings:** ASIC or any other person proposes to conduct any enquiry, investigation or proceedings, or to take any regulatory action or to seek any remedy, in connection with the Entitlement Offer or the Prospectus, or publicly announces that it intends to do so; or
- (h) **unable to issue Securities:** the Company is prevented from issuing the Underwritten Securities within the time required by the Underwriting Agreement, the Corporations Act, the Listing Rules, any statute, regulation or order of a court of competent jurisdiction or by ASIC, ASX or any government authority; or
- (i) **future matters:** any statement or estimate in the Prospectus which relates to a future matter is or becomes incapable of being met or, in the reasonable opinion of the Underwriter, unlikely to be met in the projected timeframe; or
- (j) **withdrawal of consent to Prospectus:** any person (other than the Underwriter) who has previously consented to the inclusion of its, his or her name in the Prospectus or to be named in the Prospectus, withdraws that consent; or
- (k) **no quotation approval:** the Company fails to lodge an Appendix 3B or Appendix 2A with ASX (or any other appendices required to be lodged under the Listing Rules with ASX) in relation to Shares and New Options offered pursuant to the Entitlement Offer or the Underwritten Shares with ASX within the timeframe those lodgements are required to be made; or
- (l) **ASIC application:** an application is made by ASIC for an order under section 1324B or any other provision of the Corporations Act in relation to the Prospectus, and the agreed shortfall notice deadline date has arrived, and that application has not been dismissed or withdrawn; or
- (m) **ASIC hearing:** ASIC gives notice of its intention to hold a hearing under section 739 of the Corporations Act in relation to the Prospectus to determine if it should make a stop order in relation to the Prospectus (and that hearing has not occurred by 9:00am on the settlement date specified in the Timetable (or such other date as the Company and the Underwriter agree in writing)) or ASIC makes an interim or final stop order in relation to the Prospectus under section 739 of the Corporations Act; or
- (n) **Takeovers Panel:** the Takeovers Panel makes a declaration that circumstances in relation to the Entitlement Offer (other than due to any act or omission of the Underwriter) are unacceptable circumstances under Pt 6.10 of the Corporations Act, which in the Underwriter's reasonable opinion has a material adverse effect; or
- (o) **authorisation:** any authorisation which is material to anything

referred to in the Prospectus is repealed, revoked or terminated or expires, or is modified or amended in a manner unacceptable to the Underwriter acting reasonably; or

- (p) **indictable offence:** a director or senior manager of either the Company or a subsidiary of the Company is charged with an indictable offence; or
- (q) **termination events:** any of the following events occurs:
 - (i) **hostilities:** there is an outbreak of hostilities or a material escalation of hostilities (whether or not war has been declared) after the date of the Underwriting Agreement involving one or more of Australia, New Zealand, the United Kingdom, the United States of America or the Peoples Republic of China or any member of the European Union other than hostilities involving Libya, Afghanistan, Iraq, Iran, Syria, Lebanon, Israel, Palestine, Russia or Ukraine and the Underwriter believes (on reasonable grounds) that the outbreak or escalation is likely to result in the S&P ASX 200 Index falling by the percentage contemplated in (a) above;
 - (ii) **default:** default or breach by the Company under the Underwriting Agreement of any term, condition, covenant or undertaking which is not remedied within five (5) days after receipt of written notice from the Underwriter;
 - (iii) **incorrect or untrue representation:** any representation, warranty or undertaking given by the Company in the Underwriting Agreement is or becomes untrue or incorrect in a material respect;
 - (iv) **contravention of constitution or Act:** a material contravention by the Relevant Company of any provision of its constitution, the Corporations Act, the Listing Rules or any other applicable legislation or any policy or requirement of ASIC or ASX;
 - (v) **adverse change:** an event occurs which gives rise to a material adverse effect after the date of the Underwriting Agreement in the assets, liabilities, financial position, trading results, profits, forecasts, losses, prospects, business or operations of the Relevant Company including, without limitation, if any forecast in the Prospectus becomes incapable of being met or in the Underwriter's reasonable opinion, unlikely to be met in the projected time;
 - (vi) **error in due diligence results:** it transpires that any of the due diligence results in relation to the Entitlement Offer or any part of the verification material in relation to the Entitlement Offer was, misleading or deceptive in any material respect, materially false or that there was a material omission from them;
 - (vii) **significant change:** a "new circumstance" as referred to in section 719(1) of the Corporations Act arises that is materially adverse from the point of view of an investor;
 - (viii) **public statements:** without the prior approval of the Underwriter, a public statement is made by the Company in relation to the Entitlement Offer or the Prospectus other than a statement the Company is required to make in order to comply with its continuous disclosure obligations under the Listing Rules and/or the Corporations Act;

- (ix) **misleading information:** any information supplied at any time by the Company or any person on its behalf to the Underwriter in respect of any aspect of the Entitlement Offer or the affairs of the Relevant Company is or becomes misleading or deceptive or likely to mislead or deceive in any material respect;
- (x) **Official Quotation qualified:** the ASX makes an official statement to the Company advising that it will not, or does not intend to, grant permission for the official quotation of the Underwritten Shares;
- (xi) **Prescribed Occurrence:** a prescribed occurrence occurs, other than as disclosed in the Prospectus;
- (xii) **suspension of debt payments:** the Company suspends payment of its debts generally;
- (xiii) **event of insolvency:** an event of insolvency occurs in respect of a Relevant Company;
- (xiv) **judgment against a Relevant Company:** a judgment in an amount exceeding \$100,000 is obtained against a Relevant Company and is not set aside or satisfied within seven (7) days;
- (xv) **litigation:** litigation, arbitration, administrative or industrial proceedings are, after the date of the Underwriting Agreement, commenced against any Relevant Company except as disclosed in the Prospectus;
- (xvi) **Board and senior management composition:** there is a change in the composition of the Board or a change in the senior management of the Company before the date of issue of the Underwritten Securities without the prior written consent of the Underwriter (such consent not to be unreasonably withheld);
- (xvii) **change in shareholdings:** there is a material change in the major or controlling shareholdings of a Relevant Company (other than as a result of the Entitlement Offer or a matter disclosed in the Prospectus) or a takeover offer or scheme of arrangement pursuant to Chapter 5 or 6 of the Corporations Act is publicly announced in relation to a Relevant Company;
- (xviii) **timetable:** there is a delay in any specified date in the Timetable which is greater than 3 Business Days;
- (xix) **force majeure:** a Force Majeure affecting the Company's business or any obligation under the Underwriting Agreement lasting in excess of seven (7) days occurs;
- (xx) **certain resolutions passed:** a Relevant Company passes or takes any steps to pass a resolution under section 254N, section 257A or section 260B of the Corporations Act or a resolution to amend its constitution without the prior written consent of the Underwriter;
- (xxi) **capital structure:** any Relevant Company alters its capital structure in any manner not contemplated by the Prospectus excluding the issue of any Shares upon exercise of Options, such Options having been disclosed to the ASX as at the date of the Underwriting Agreement, a proposed issue disclosed in the offer materials, an agreement announced to the ASX prior to the date of the Underwriting Agreement an issue under an employee incentive scheme, a non-underwritten

	dividend reinvestment or a bonus share plan as disclosed to ASX in accordance with the Listing Rules prior to the date of the Underwriting Agreement; or (xxii) breach of contracts: any material agreement of the Company as publicly disclosed to ASX together with any other material agreements described in the Prospectus is materially breached, terminated, purported to be terminated or substantially modified; (xxiii) market conditions: for more than two (2) Business Days, a suspension or material limitation in trading generally on ASX occurs or any material adverse change or disruption occurs in the existing financial markets, political or economic conditions of Australia, Japan, the United Kingdom, the United States of America or other international financial markets. The events listed in paragraph (q) do not entitle the Underwriter to exercise its rights to terminate unless, in the reasonable opinion of the Underwriter reached in good faith, any event has or is likely to have, or those events together have, or could reasonably be expected to have, a material adverse effect or could give rise to a liability of the Underwriter under the Corporations Act.
Liability to pay third party fees	For the avoidance of doubt, the Company is not liable to pay any fees to any third parties where applicable for sub-underwriting or placing of the Shortfall Securities.
Other	The Underwriting Agreement otherwise contains provisions considered standard for an agreement of its nature (including representations and warranties and confidentiality provisions).

SCHEDULE 4 – TERMS AND CONDITIONS OF PERFORMANCE RIGHTS

1.	Entitlement	Each Performance Right entitles the holder to subscribe for one Share upon conversion of the Performance Right.								
2.	Consideration	The Performance Rights will be issued for nil consideration and no consideration will be payable upon the conversion of the Performance Rights into Shares.								
3.	Vesting Conditions	The Performance Rights shall vest as follows: <table><tr><th>CLASS</th><th>VESTING CONDITION</th></tr><tr><td>A</td><td>The market capitalisation of the Company exceeding a value of \$13.5 million measured over a 5-day volume weighted average price (VWAP) of the Company's Shares.</td></tr><tr><td>B</td><td>The market capitalisation of the Company exceeding a value of \$16.0 million measured over a 5-day VWAP of the Company's Shares.</td></tr><tr><td>C</td><td>The market capitalisation of the Company exceeding a value of \$18.0 million measured over a 5-day VWAP of the Company's Shares.</td></tr></table> each, a Vesting Condition.	CLASS	VESTING CONDITION	A	The market capitalisation of the Company exceeding a value of \$13.5 million measured over a 5-day volume weighted average price (VWAP) of the Company's Shares.	B	The market capitalisation of the Company exceeding a value of \$16.0 million measured over a 5-day VWAP of the Company's Shares.	C	The market capitalisation of the Company exceeding a value of \$18.0 million measured over a 5-day VWAP of the Company's Shares.
CLASS	VESTING CONDITION									
A	The market capitalisation of the Company exceeding a value of \$13.5 million measured over a 5-day volume weighted average price (VWAP) of the Company's Shares.									
B	The market capitalisation of the Company exceeding a value of \$16.0 million measured over a 5-day VWAP of the Company's Shares.									
C	The market capitalisation of the Company exceeding a value of \$18.0 million measured over a 5-day VWAP of the Company's Shares.									
4.	Expiry Date	The Performance Rights, whether vested or unvested, will otherwise expire at 5:00 pm (WST) as follows: <table><tr><th>CLASS</th><th>EXPIRY DATE</th></tr><tr><td>A</td><td rowspan="3">The date that is three (3) years from the grant of the Performance Rights.</td></tr><tr><td>B</td></tr><tr><td>C</td></tr></table> Each, an Expiry Date. If the relevant Vesting Condition attached to the Performance Right has not been achieved by the Expiry Date, all unconverted Performance Rights of the relevant tranche will automatically lapse at that time.	CLASS	EXPIRY DATE	A	The date that is three (3) years from the grant of the Performance Rights.	B	C		
CLASS	EXPIRY DATE									
A	The date that is three (3) years from the grant of the Performance Rights.									
B										
C										
5.	Notice of vesting	The Company shall notify the holder in writing when the relevant Vesting Condition has been satisfied.								
6.	Quotation of Performance Rights	The Performance Rights will not be quoted on ASX.								
7.	Conversion	Subject to paragraph 16, upon vesting, each Performance Right will, at the election of the holder, convert into one Share.								
8.	Timing of issue of Shares on conversion	Within five Business Days of conversion of the Performance Rights, the Company will: (a) issue the number of Shares required under these terms and conditions in respect of the number of Performance Rights converted; (b) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and								

		(c) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Performance Rights. If a notice delivered under 8(b) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.
9.	Shares issued on exercise	Shares issued on exercise of the Performance Rights rank equally with the then issued shares of the Company.
10.	Change of Control	Subject to paragraph 16, upon: (a) a bona fide takeover bid under Chapter 6 of the Corporations Act having been made in respect of the Company and: (i) having received acceptances for not less than 50.1% of the Company's Shares on issue; and (ii) having been declared unconditional by the bidder; or (b) a court granting orders approving a compromise or arrangement for the purposes of or in connection with a scheme for the reconstruction of the Company or its amalgamation with any other company or companies, then, to the extent Performance Rights have not converted into Shares due to satisfaction of the relevant Vesting Conditions, Performance Rights will accelerate vesting conditions and will automatically convert into Shares on a one-for-one basis.
11.	Participation in new issues	There are no participation rights or entitlements inherent in the Performance Rights and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Performance Rights without converting the Performance Rights.
12.	Adjustment for bonus issues of Shares	If the Company makes a bonus issue of Shares or other securities to the Company's existing shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment no changes will be made to the Performance Rights.
13.	Reorganisation	If at any time the issued capital of the Company is reorganised (including consolidation, subdivision, reduction or return), all rights of a holder will be changed in a manner consistent with the applicable ASX Listing Rules and the Corporations Act at the time of reorganisation.
14.	Dividend and voting rights	The Performance Rights do not confer on the holder an entitlement to vote (except as otherwise required by law) or receive dividends.
15.	Transferability	The Performance Rights are not transferable.
16.	Deferral of conversion if resulting in a prohibited acquisition of Shares	If the conversion of a Performance Right under paragraphs 7 or 10 would result in any person being in contravention of section 606(1) of the Corporations Act (General Prohibition) then the conversion of that Performance Right shall be deferred until such later time or times that the conversion would not result in a contravention of the General Prohibition. In assessing whether a conversion of a Performance Right would result in a contravention of the General Prohibition: (a) holders may give written notification to the Company if they consider that the conversion of a Performance Right may

		result in the contravention of the General Prohibition. The absence of such written notification from the holder will entitle the Company to assume the conversion of a Performance Right will not result in any person being in contravention of the General Prohibition; and (b) the Company may (but is not obliged to) by written notice to a holder request a holder to provide the written notice referred to in paragraph 16(a) within 7 days if the Company considers that the conversion of a Performance Right may result in a contravention of the General Prohibition. The absence of such written notification from the holder will entitle the Company to assume the conversion of a Performance Right will not result in any person being in contravention of the General Prohibition.
17.	No rights to return of capital	A Performance Right does not entitle the holder to a return of capital, whether in a winding up, upon a reduction of capital or otherwise.
18.	Rights on winding up	A Performance Right does not entitle the holder to participate in the surplus profits or assets of the Company upon winding up.
19.	ASX Listing Rule compliance	The Board reserves the right to amend any term of the Performance Rights to ensure compliance with the ASX Listing Rules.
20.	No other rights	A Performance Right gives the holder no rights other than those expressly provided by these terms and conditions and those provided at law where such rights at law cannot be excluded by these terms.

SCHEDULE 5 – VALUATION OF PERFORMANCE RIGHTS

The Performance Rights to be issued pursuant to Resolutions 9 to 11 have been independently valued.

Using the Black & Scholes pricing model and based on the assumptions set out below, the Performance Rights were ascribed the following value range:

ASSUMPTIONS:	CLASS A	CLASS B	CLASS C
Valuation date	15 October 2025	15 October 2025	15 October 2025
Market price of Shares	\$0.071	\$0.071	\$0.071
Vesting period	Three (3) years	Three (3) years	Three (3) years
Vesting date	15 October 2025	15 October 2025	15 October 2025
Expiry date (length of time from issue)	The date that is three (3) years from the grant of the Performance Rights.	The date that is three (3) years from the grant of the Performance Rights.	The date that is three (3) years from the grant of the Performance Rights.
Risk free interest rate	3.49%	3.49%	3.49%
Volatility	84.9%	84.9%	84.9%
Indicative value per Performance Right	\$0.0594	\$0.0559	\$0.0533
Total Value of Performance Rights	\$297,146	\$279,636	\$266,723
Mr Gavin Rezos (Resolution 9)	\$118,858	\$111,854	\$106,689
Mr Brendan Borg (Resolution 10)	\$89,144	\$83,891	\$80,017
Ms Maja McGuire (Resolution 11)	\$89,144	\$83,891	\$80,017

Note: The valuation ranges noted above are not necessarily the market prices that the Performance Rights could be traded at and they are not automatically the market prices for taxation purposes.

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Your proxy voting instruction must be received by **2:30pm (AWST) on Monday, 01 December 2025**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://investor.automic.com.au/#/loginsah> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

